(BIIB) Biogen - Ratings and Ratios
Therapies, Multiple Sclerosis, Biosimilars, Neurological Diseases, Medications
BIIB EPS (Earnings per Share)
BIIB Revenue
Description: BIIB Biogen
Biogen Inc. is a leading biotechnology company that focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The companys product portfolio includes a range of treatments for multiple sclerosis, spinal muscular atrophy, and other serious conditions. Key products include TECFIDERA, VUMERITY, and OCREVUS, which are used to treat multiple sclerosis, as well as SPINRAZA, which is used to treat spinal muscular atrophy.
From a business perspective, Biogen has established partnerships with several major pharmaceutical companies, including Genentech, Eisai, and Ionis Pharmaceuticals, to develop and commercialize new treatments. The company has also made significant investments in research and development, with a focus on emerging areas such as Alzheimers disease and Parkinsons disease. Key performance indicators (KPIs) to watch include revenue growth, R&D expenditure as a percentage of revenue, and the success of new product launches.
Some key metrics to evaluate Biogens performance include its market share in the multiple sclerosis treatment market, the uptake of its newer products such as VUMERITY, and the progress of its pipeline assets, including its biosimilars portfolio. With a strong pipeline and a solid financial position, Biogen is well-positioned to continue to drive growth and innovation in the biotechnology sector. Notable KPIs include: Revenue: $13.4B (FY2022), R&D expenses: $2.3B (FY2022), and Gross Margin: 83.4% (FY2022).
To further analyze Biogens prospects, its essential to monitor its ability to execute on its pipeline, navigate the competitive landscape, and address potential pricing pressures in key markets. The companys return on equity (RoE) of 8.97% and forward P/E ratio of 8.90 suggest a relatively attractive valuation compared to some of its peers. However, a more detailed analysis of its financials and operational metrics is necessary to form a comprehensive view of the companys investment potential.
BIIB Stock Overview
| Market Cap in USD | 20,909m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-09-16 |
BIIB Stock Ratings
| Growth Rating | -60.6% |
| Fundamental | 62.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -38.3% |
| Analyst Rating | 3.81 of 5 |
BIIB Dividends
Currently no dividends paidBIIB Growth Ratios
| Growth Correlation 3m | 79.4% |
| Growth Correlation 12m | -75.7% |
| Growth Correlation 5y | -65.6% |
| CAGR 5y | -10.60% |
| CAGR/Max DD 3y | -0.16 |
| CAGR/Mean DD 3y | -0.37 |
| Sharpe Ratio 12m | -1.39 |
| Alpha | 0.00 |
| Beta | 0.787 |
| Volatility | 26.50% |
| Current Volume | 1514.4k |
| Average Volume 20d | 1514.4k |
| Stop Loss | 137.9 (-4.1%) |
| Signal | 0.54 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (1.53b TTM) > 0 and > 6% of Revenue (6% = 599.8m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 47.85% (prev 41.36%; Δ 6.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.12b > Net Income 1.53b (YES >=105%, WARN >=100%) |
| Net Debt (3.84b) to EBITDA (2.79b) ratio: 1.37 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (145.9m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 75.43% (prev 75.54%; Δ -0.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.26% (prev 36.08%; Δ 0.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.12 (EBITDA TTM 2.79b / Interest Expense TTM 252.4m) >= 6 (WARN >= 3) |
Altman Z'' 5.88
| (A) 0.17 = (Total Current Assets 7.97b - Total Current Liabilities 3.18b) / Total Assets 28.33b |
| (B) 0.71 = Retained Earnings (Balance) 20.14b / Total Assets 28.33b |
| (C) 0.07 = EBIT TTM 2.05b / Avg Total Assets 27.57b |
| (D) 1.86 = Book Value of Equity 19.90b / Total Liabilities 10.70b |
| Total Rating: 5.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.41
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.72% = 3.36 |
| 3. FCF Margin 18.57% = 4.64 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 3.39 = -2.22 |
| 6. ROIC - WACC (= 1.18)% = 1.47 |
| 7. RoE 9.04% = 0.75 |
| 8. Rev. Trend 1.89% = 0.14 |
| 9. EPS Trend -2.01% = -0.10 |
What is the price of BIIB shares?
Over the past week, the price has changed by +1.58%, over one month by +6.59%, over three months by +14.47% and over the past year by -26.91%.
Is Biogen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIIB is around 130.12 USD . This means that BIIB is currently overvalued and has a potential downside of -9.52%.
Is BIIB a buy, sell or hold?
- Strong Buy: 13
- Buy: 4
- Hold: 20
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BIIB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 172 | 19.6% |
| Analysts Target Price | 172 | 19.6% |
| ValueRay Target Price | 142.4 | -1% |
Last update: 2025-09-12 04:32
BIIB Fundamental Data Overview
CCE Cash And Equivalents = 2.76b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 13.6469
P/E Forward = 8.9606
P/S = 2.0915
P/B = 1.1939
P/EG = 6.2424
Beta = 0.112
Revenue TTM = 10.00b USD
EBIT TTM = 2.05b USD
EBITDA TTM = 2.79b USD
Long Term Debt = 6.28b USD (from longTermDebt, last quarter)
Short Term Debt = 3.18b USD (from totalCurrentLiabilities, last quarter)
Debt = 9.47b USD (Calculated: Short Term 3.18b + Long Term 6.28b)
Net Debt = 3.84b USD (from netDebt column, last quarter)
Enterprise Value = 27.62b USD (20.91b + Debt 9.47b - CCE 2.76b)
Interest Coverage Ratio = 8.12 (Ebit TTM 2.05b / Interest Expense TTM 252.4m)
FCF Yield = 6.72% (FCF TTM 1.86b / Enterprise Value 27.62b)
FCF Margin = 18.57% (FCF TTM 1.86b / Revenue TTM 10.00b)
Net Margin = 15.31% (Net Income TTM 1.53b / Revenue TTM 10.00b)
Gross Margin = 75.43% ((Revenue TTM 10.00b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 27.62b / Book Value Of Equity 19.90b)
Interest Expense / Debt = 0.77% (Interest Expense 72.6m / Debt 9.47b)
Taxrate = 14.37% (273.8m / 1.91b)
NOPAT = 1.76b (EBIT 2.05b * (1 - 14.37%))
Current Ratio = 2.50 (Total Current Assets 7.97b / Total Current Liabilities 3.18b)
Debt / Equity = 0.54 (Debt 9.47b / last Quarter total Stockholder Equity 17.63b)
Debt / EBITDA = 3.39 (Net Debt 3.84b / EBITDA 2.79b)
Debt / FCF = 5.10 (Debt 9.47b / FCF TTM 1.86b)
Total Stockholder Equity = 16.92b (last 4 quarters mean)
RoA = 5.40% (Net Income 1.53b, Total Assets 28.33b )
RoE = 9.04% (Net Income TTM 1.53b / Total Stockholder Equity 16.92b)
RoCE = 8.83% (Ebit 2.05b / (Equity 16.92b + L.T.Debt 6.28b))
RoIC = 7.56% (NOPAT 1.76b / Invested Capital 23.21b)
WACC = 6.39% (E(20.91b)/V(30.38b) * Re(8.98%)) + (D(9.47b)/V(30.38b) * Rd(0.77%) * (1-Tc(0.14)))
Shares Correlation 3-Years: 73.70 | Cagr: 0.07%
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.78% ; FCFE base≈1.70b ; Y1≈1.79b ; Y5≈2.12b
Fair Price DCF = 213.4 (DCF Value 31.28b / Shares Outstanding 146.6m; 5y FCF grow 5.94% → 3.0% )
EPS Correlation: -2.01 | EPS CAGR: 5.11% | SUE: 4.0 | # QB: 1
Revenue Correlation: 1.89 | Revenue CAGR: 1.95% | SUE: 4.0 | # QB: 2
Additional Sources for BIIB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle